XTX Topco Ltd Buys 225,823 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN)

XTX Topco Ltd raised its stake in shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) by 186.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 347,255 shares of the company’s stock after acquiring an additional 225,823 shares during the period. XTX Topco Ltd owned about 0.28% of Mersana Therapeutics worth $656,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of MRSN. US Bancorp DE bought a new stake in shares of Mersana Therapeutics during the 3rd quarter worth $31,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of Mersana Therapeutics during the 3rd quarter worth $34,000. Intech Investment Management LLC purchased a new stake in Mersana Therapeutics in the 3rd quarter worth about $52,000. Quarry LP purchased a new stake in Mersana Therapeutics in the 3rd quarter worth about $57,000. Finally, Algert Global LLC purchased a new position in Mersana Therapeutics during the 2nd quarter valued at about $90,000. 93.92% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Separately, Citigroup assumed coverage on Mersana Therapeutics in a report on Friday, November 15th. They set a “buy” rating and a $5.00 price objective for the company. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $6.00.

Mersana Therapeutics Price Performance

Shares of MRSN stock opened at $2.30 on Friday. The stock has a market cap of $284.13 million, a price-to-earnings ratio of -3.77 and a beta of 1.40. The business’s fifty day moving average is $2.17 and its 200 day moving average is $1.98. Mersana Therapeutics, Inc. has a twelve month low of $1.22 and a twelve month high of $6.28. The company has a quick ratio of 2.35, a current ratio of 2.35 and a debt-to-equity ratio of 13.35.

Mersana Therapeutics (NASDAQ:MRSN) last issued its quarterly earnings results on Wednesday, November 13th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.08. The company had revenue of $12.60 million for the quarter, compared to analysts’ expectations of $7.53 million. Mersana Therapeutics had a negative return on equity of 401.37% and a negative net margin of 214.20%. The firm’s revenue for the quarter was up 63.6% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.35) earnings per share. Research analysts expect that Mersana Therapeutics, Inc. will post -0.61 EPS for the current fiscal year.

About Mersana Therapeutics

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.